Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects

被引：0
|
作者：
Yong Zeng
Yi-jing He
Fu-yuan He
Lan Fan
Hong-hao Zhou
机构：
[1] Pharmacogenetics Research Institute,
[2] Institute of Clinical Pharmacology,undefined
[3] Central South University,undefined
来源：
Acta Pharmacologica Sinica | 2009年 / 30卷
关键词：
bifendate; cyclosporine; pharmacokinetics; CYP3A4; 18B;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：478 / 484
页数：6
相关论文
共 50 条
  • [41] Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation
    Hu, Yong-Fang
    Qiu, Wen
    Liu, Zhao-Qian
    Zhu, Li-Jun
    Liu, Zhong-Qi
    Tu, Jiang-Hua
    Wang, Dan
    Li, Zhi
    He, Jun
    Zhong, Gan-Ping
    Zhou, Gan
    Zhou, Hong-Hao
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (11) : 1093 - 1098
  • [42] CYP3A5 Genotype, but Not CYP3A4*1B, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients
    Santoro, A. B.
    Struchiner, C. J.
    Felipe, C. R.
    Tedesco-Silva, H.
    Medina-Pestana, J. O.
    Suarez-Kurtz, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 201 - 202
  • [43] Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone
    Oliver Kummer
    Felix Hammann
    Claudine Moser
    Olivier Schaller
    Jürgen Drewe
    Stephan Krähenbühl
    European Journal of Clinical Pharmacology, 2011, 67 : 63 - 71
  • [44] The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition
    Jiang, Fen
    Choi, Jong-Yeol
    Lee, Ju-Hyun
    Ryu, Sunae
    Park, Ze-Won
    Lee, Jong-Gu
    Na, Han-Sung
    Lee, Seok-Yong
    Oh, Woo-Yong
    Chung, Myeon-Woo
    Choi, Seung-Eun
    PHARMACOGENOMICS, 2017, 18 (05) : 459 - 469
  • [45] Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function
    Orlando, R
    Piccoli, P
    De Martin, S
    Padrini, R
    Palatini, P
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (01) : 86 - 93
  • [46] The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
    Shi, Jack G.
    Chen, Xuejun
    Emm, Thomas
    Scherle, Peggy A.
    McGee, Ryan F.
    Lo, Yvonne
    Landman, Robert R.
    McKeever, Edward G., Jr.
    Punwani, Naresh G.
    Williams, William V.
    Yeleswaram, Swamy
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (06) : 809 - 818
  • [47] The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel
    Nleya, Lovejoy
    Thelingwani, Roslyn
    Li, Xue-Qing
    Cavallin, Erika
    Isin, Emre
    Nhachi, Charles
    Masimirembwa, Collen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (08) : 1077 - 1087
  • [48] Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects
    Trivedi, Ashit
    Malik, Fady, I
    Jafarinasabian, Pegah
    Zhang, Hanze
    Flach, Stephen
    Abbasi, Siddique
    Dutta, Sandeep
    Lee, Edward
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (02): : 185 - 193
  • [49] Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma
    Chugh, Rashmi
    Wagner, Thomas
    Griffith, Kent A.
    Taylor, Jeremy M. G.
    Thomas, Dafydd G.
    Worden, Francis P.
    Leu, Kirsten M.
    Zalupski, Mark M.
    Baker, Laurence H.
    CANCER, 2007, 109 (11) : 2315 - 2322
  • [50] Effect of a new functional CYP3A4 polymorphism on cyclosporine dose requirement and trough blood levels in stable renal transplant patients
    Elens, L.
    van Schaik, R.
    Panin, N.
    De Meyer, M.
    Wallemacq, P.
    Lison, D.
    Mourad, M.
    Haufroid, V
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 506 - 507
12345